Chest wall reconstruction with implantable cross-linked porcine dermal collagen matrix: Evaluation of clinical outcomes
| Autor: | Alessandro Gonfiotti, Domenico Viggiano, Eduart Vokrri, Marco Lucchi, Duilio Divisi, Roberto Crisci, Felice Mucilli, Federico Venuta, Luca Voltolini |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
latissimus dorsi
polytetrafluoroethylene Pulmonary and Respiratory Medicine biological mesh PM PMCWT cross-linked porcine dermal collagen matrix LD secondary chest wall tumor CWR chest wall reconstruction LD latissimus dorsi PACLIDEM porcine-derived acellular cross-linked dermal matrix PCWT primary chest wall tumor PM pectoral major PMCWT primary malignant chest wall tumor PTFE polytetrafluoroethylene SCWT secondary chest wall tumor chest wall reconstruction chest wall tumor titanium bar PACLIDEM PCWT SCWT CWR primary malignant chest wall tumor porcine-derived acellular cross-linked dermal matrix primary chest wall tumor Surgery pectoral major PTFE |
| Zdroj: | JTCVS Techniques. 13:250-260 |
| ISSN: | 2666-2507 |
| DOI: | 10.1016/j.xjtc.2022.01.021 |
| Popis: | The aim of the study is to evaluate clinical applications, safety, and effectiveness of a porcine-derived acellular cross-linked dermal matrix biological mesh in chest wall reconstruction.We retrospectively analyzed a prospective multicenter database of chest wall reconstructions using a biological mesh in adult patients undergoing operation between October 2013 and December 2020. We evaluated preoperative data, type of resection and reconstruction, hospitalization, 30-day morbidity and mortality, and overall survival.A total of 105 patients (36 women [34.2%]; mean age, 57.0 ± 16.1 years; range, 18-90 years) were included, they have admitted for: primary chest wall tumor (n = 52; 49.5%), secondary chest wall tumor (n = 29; 27.6%), lung hernia (n = 12; 11.4%), trauma (n = 10; 9.6%), and infections (n = 2; 1.9%). The surgical sites were preoperatively defined as at high risk of infection in 28 patients (26.7%) or as infected in 16 (15.2%) patients. Thirty-days morbidity was 30.5% (n = 32 patients); 14 patients (13.3%) had postoperative complications directly related to chest wall surgical resection and/or reconstruction. We experienced no 30-day mortality; 1-year and 2-year mortality was 8.4% and 16.8%, respectively.Biological mesh represents a valuable option in chest wall reconstruction even when surgical sites are infected or at high-risk of infections. This mesh shows low early and late postoperative complication rates and excellent long-term stability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|